Naptumomab estafenatox

Drug Profile

Naptumomab estafenatox

Alternative Names: ABR-217620; Anyara; TTS CD3

Latest Information Update: 28 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Non-small cell lung cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 26 Oct 2016 NeoTX plans a clinical trial for Cancer in Israel
  • 26 Oct 2016 Active Biotech enters into a licensing agreement with NeoTX Therapeutics for the worldwide development and commercialisation of the Naptumomab estafenatox.
  • 01 Jun 2015 Naptumomab estafenatox is still available for licensing as of June 2015 (http://www.activebiotech.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top